Do drug treatment variables predict cognitive performance in multidrug-treated opioid-dependent patients? A regression analysis study

Substance Abuse Treatment, Prevention, and Policy

Hannu Alho¹  Hely Kalska³  Carola Fabritius²  Pekka Rapeli³ 

[1] Research Unit of Substance Abuse Medicine, University of Helsinki, Helsinki, Finland;Department of Mental Health and Substance Abuse Services, National Institute for Health and Welfare (THL), Helsinki, Finland;Institute of Behavioural Sciences, University of Helsinki, Helsinki, Finland

关键词: Neuropsychological testing;    Neurocognitive performance;    Psychotropic drugs;    Pharmacotherapy;    Opioid agonist therapy;    Opioid-dependence;   

Others  :  834460
DOI  :  10.1186/1747-597X-7-45

 received in 2012-06-22, accepted in 2012-10-23,  发布年份 2012

【 摘 要 】

Background

Cognitive deficits and multiple psychoactive drug regimens are both common in patients treated for opioid-dependence. Therefore, we examined whether the cognitive performance of patients in opioid-substitution treatment (OST) is associated with their drug treatment variables.

Methods

Opioid-dependent patients (N = 104) who were treated either with buprenorphine or methadone (n = 52 in both groups) were given attention, working memory, verbal, and visual memory tests after they had been a minimum of six months in treatment. Group-wise results were analysed by analysis of variance. Predictors of cognitive performance were examined by hierarchical regression analysis.

Results

Buprenorphine-treated patients performed statistically significantly better in a simple reaction time test than methadone-treated ones. No other significant differences between groups in cognitive performance were found. In each OST drug group, approximately 10% of the attention performance could be predicted by drug treatment variables. Use of benzodiazepine medication predicted about 10% of performance variance in working memory. Treatment with more than one other psychoactive drug (than opioid or BZD) and frequent substance abuse during the past month predicted about 20% of verbal memory performance.

Conclusions

Although this study does not prove a causal relationship between multiple prescription drug use and poor cognitive functioning, the results are relevant for psychosocial recovery, vocational rehabilitation, and psychological treatment of OST patients. Especially for patients with BZD treatment, other treatment options should be actively sought.

【 授权许可】

   
2012 Rapeli et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]United Nations Office on Drugs and Crime: 2007 World Drug Report. Vienna: United Nations Office on Drugs and Crime; 2007.
• [2]Brooner RK, King VL, Kidorf M, Schmidt CW, Bigelow GE: Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psych 1997, 54:71-80.
• [3]Abou-Saleh MT, Janca A: The epidemiology of substance misuse and comorbid psychiatric disorders. Acta Neuropsychiatr 2004, 16:3-8.
• [4]Strain EC: Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients. Clin J Pain 2002, 18:S14-S27.
• [5]Lee HY, Li JH, Wu LT, Wu JS, Yen CF, Tang HP: Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan. Subst Abuse Treat Prev Policy 2012, 7:11. BioMed Central Full Text
• [6]Deering D, Horn J, Frampton CMA: Clients' perceptions of opioid substitution treatment: An input to improving the quality of treatment. Int J Ment Health Nurs 2012, 21:330-339.
• [7]Bramness JG, Kornor H: Benzodiazepine prescription for patients in opioid maintenance treatment in Norway. Drug Alcohol Depend 2007, 90:203-209.
• [8]Eiroa-Orosa FJ, Haasen C, Verthein U, Dilg C, Schafer I, Reimer J: Benzodiazepine use among patients in heroin-assisted vs methadone maintenance treatment Findings of the German randomized controlled trial. Drug Alcohol Depend 2010, 112:226-233.
• [9]Schreiber S, Peles E, Adelson M: Association between improvement in depression, reduced benzodiazepine (BDZ) abuse, and increased psychotropic medication use in methadone maintenance treatment (MMT) patients. Drug Alcohol Depend 2008, 92:79-85.
• [10]Soyka M, Horak M, Dittert S, Kagerer S: Less driving impairment on buprenorphine than methadone in drug-dependent patients? J Neuropsychiatry Clin Neurosci 2001, 13:527-528.
• [11]Soyka M, Lieb M, Kagerer S, Zingg C, Koller G, Lehnert P, Limmer C, Kuefner H, Hennig-Fast K: Cognitive functioning during methadone and buprenorphine treatment results of a randomized clinical trial. J Clin Psychopharmacol 2008, 28:699-703.
• [12]Giacomuzzi SM, Thill C, Riemer Y, Garber K, Ertl M: Buprenorphine-and methadone maintenance treatment: influence on aspects of cognitive and memory performance. Open Addict J 2008, 1:5-6.
• [13]Pirastu R, Fais R, Messina M, Bini V, Spiga S, Falconieri D, Diana M: Impaired decision-making in opiate-dependent subjects: effect of pharmacological therapies. Drug Alcohol Depend 2006, 83:163-168.
• [14]Soyka M, Limmer C, Lehnert R, Koller G, Martin G, Kuefner H, Kagerer S, Haberthuer A: A Comparison of Cognitive Function in Patients under Maintenance Treatment with Heroin, Methadone, or Buprenorphine and Healthy Controls: An Open Pilot Study. Am J Drug Alcohol Abuse 2011, 37:497-508.
• [15]De Maeyer J, Vanderplasschen W, Lammertyn J, van Nieuwenhuizen C, Sabbe B, Broekaert E: Current quality of life and its determinants among opiate-dependent individuals five years after starting methadone treatment. Qual Life Res 2011, 20:139-150.
• [16]Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RSE, McDonald K, Ward A, Poulton R, Moffitt TE: Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA 2012, 109:1-8.
• [17]McCowan C, Kidd B, Fahey T: Factors associated with mortality in Scottish patients receiving methadone in primary care: retrospective cohort study. BMJ 2009, 338:b2225.
• [18]Pil K, Raes E, Van den Neste T, Goessaert A-S, Veramme J, Verstraete A: Review of existing classification efforts. In DRUID Driving under the Influence of Drugs, Alcohol and Medicines Project co-funded by the European Commission within the Sixth Framework Programme (2002–2006). Belgium: Ghent University; 2008.
• [19]Rapeli P, Fabritius C, Kalska H, Alho H: Memory function in opioid-dependent patients treated with methadone or buprenorphine along with benzodiazepine: longitudinal change in comparison to healthy individuals. Subst Abuse Treat Prev Policy 2009, 4:6. BioMed Central Full Text
• [20]Lintzeris N, Mitchell TB, Bond A, Nestor L, Strang J: Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients. J Clin Psychopharmacol 2006, 26:274-283.
• [21]Lintzeris N, Mitchell TB, Bond AJ, Nestor L, Strang J: Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients. Drug Alcohol Depend 2007, 91:187-194.
• [22]Rapeli P, Fabritius C, Kalska H, Alho H: Cognitive functioning in opioid-dependent patients treated with buprenorphine, methadone, and other psychoactive medications: stability and correlates. BMC Clin Pharmacol 2011, 11:13. BioMed Central Full Text
• [23]Spiga S, Lintas A, Diana M: Addiction and Cognitive Functions. In Drug Addiction: Research Frontiers and Treatment Advances. 1139 edition. Edited by Kuhar MJ. Oxford: Blackwell Publishing; 2008:299-306.
• [24]Barker MJ, Greenwood KM, Jackson M, Crowe SF: Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 2004, 18:37-48.
• [25]Cancelli I, Beltrame M, Gigli GL, Valente M: Drugs with anticholinergic properties: cognitive and neuropsychiatric side-effects in elderly patients. Neurol Sci 2009, 30:87-92.
• [26]Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Mahmoud RA, Kirshner MA, Sorisio DA, Bies RR, Gharabawi G: Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 2008, 56:1333-1341.
• [27]Meador KJ: Cognitive side effects of medications. Neurol Clin 1998, 16:141-155.
• [28]Starr JM, McGurn B, Whiteman M, Pattie A, Whalley LJ, Deary IJ: Life long changes in cognitive ability are associated with prescribed medications in old age. Int J Geriatr Psychiatry 2004, 19:327-332.
• [29]First MB, Gibbon M, Spitzer R, Williams JB, Benjamin L: Structured Clinical Interview for DSM-IV, Axis I Disorders (SCID-I). New York: American Psychiatric Press; 1997.
• [30]Wechsler D: Wechsler Adult Intelligence Scale - Revised (WAIS-R). Finnish version. Helsinki: Psykologien Kustannus; 1993.
• [31]Chiang CN, Hawks RL: Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend 2003, 70:S39-S47.
• [32]Orman JS, Keating GM: Buprenorphine/Naloxone a review of its use in the treatment of opioid dependence. Drugs 2009, 69:577-607.
• [33]Harris DS, Mendelson JE, Lin ET, Upton RA, Jones RT: Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality. Clin Pharmacokinet 2004, 43:329-340.
• [34]Nelson J, Chouinard G: Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Can J Clin Pharmacol 1999, 6:69-83.
• [35]Nocon A, Wittchen HU, Pfister H, Zimmermann P, Lieb R: Dependence symptoms in young cannabis users? A prospective epidemiological study. J Psychiatr Res 2006, 40:394-403.
• [36]Shakeshaft AP, Bowman JA, Sanson-Fisher RW: A comparison of two retrospective measures of weekly alcohol consumption: diary and quantity/frequency index. Alcohol Alcohol 1999, 34:636-645.
• [37]Wadsworth EJK, Moss SC, Simpson SA, Smith AP: Cannabis use, cognitive performance and mood in a sample of workers. J Psychopharmacol 2006, 20:14-23.
• [38]Bava S, Tapert SF: Adolescent Brain Development and the Risk for Alcohol and Other Drug Problems. Neuropsychol Rev 2010, 20:398-413.
• [39]Effect Size Calculator http://www.cemcentre.org/renderpage.asp?linkID=30325017 webcite
• [40]Zimmermann P, Fimm B: Test for Attentional Performance (TAP). Herzogenrath: PsyTest; 1995.
• [41]Wechsler D: Wechler Memory Scale - Third Edtion. San Antonio, TX: The Psychological Corporation; 1997.
• [42]Benton A: The Revised Visual Retention Test. New York: Psychological Corporation; 1963.
• [43]Walker PW, Klein D, Kasza L: High dose methadone and ventricular arrhythmias: a report of three cases. Pain 2003, 103:321-324.
• [44]Gerard AB, McElroy MK, Taylor MJ, Grant I, Powell FL, Holverda S, Sentse N, West JB: Six percent oxygen enrichment of room air at simulated 5000 m altitude improves neuropsychological function. High Alt Med Biol 2000, 1:51-61.
• [45]Escher M, Daali Y, Chabert J, Hopfgartner G, Dayer P, Desmeules J: Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: A randomized, double-blind, placebo-controlled, crossover study. Clin Ther 2007, 29:1620-1631.
• [46]Dyer KR, White JM, Foster DJR, Bochner H, Menelaou A, Somogyi AA: The relationship between mood state and plasma methadone concentration in maintenance patients. J Clin Psychopharmacol 2001, 21:78-84.
• [47]Eap CB, Buclin T, Baumann P: Interindividual variability of the clinical pharmacokinetics of methadone - Implications for the treatment of opioid dependence. Clin Pharmacokinet 2002, 41:1153-1193.
• [48]Ragnehed M, Hakansson I, Nilsson M, Lundberg P, Soderfeldt B, Engstrom M: Influence of diazepam on clinically designed FMRI. J Neuropsychiatry Clin Neurosci 2007, 19:164-172.
• [49]Stewart SA: The effects of benzodiazepines on cognition. J Clin Psychiatry 2005, 66:9-13.
• [50]Fortin MP, Rouch I, Dauphinot V, Gedeon C, Genthon S, Bonnefoy M, Krolak-Salmon P: Effects of Anticholinergic Drugs on Verbal Episodic Memory Function in the Elderly A Retrospective, Cross-Sectional Study. Drugs Aging 2011, 28:195-204.
• [51]Horner MD, Waid LR, Johnson DE, Latham PK, Anton RF: The relationship of cognitive functioning to amount of recent and lifetime alcohol consumption in outpatient alcoholics. Addict Behav 1999, 24:449-453.
• [52]Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D: Neuropsychological performance in long-term cannabis users. Arch Gen Psych 2001, 58:909-915.
• [53]Bramness JG, Skurtveit S, Morland J, Engeland A: An increased risk of motor vehicle accidents after prescription of methadone. Addiction 2012, 107:967-972.
• [54]Corsenac P, Lagarde E, Gadegbeku B, Delorme B, Tricotel A, Castot A, Moore N, Philip P, Laumon B, Orriols L: Road traffic crashes and prescribed methadone and buprenorphine: A french registry-based case–control study. Drug Alcohol Depend 2012, 123:91-97.
• [55]Baddeley A: Working memory: Looking back and looking forward. Nat Rev Neurosci 2003, 4:829-839.
• [56]Würz A, Sungur MZ: Combining Cognitive Behavioural Therapy and Pharmacotherapy in the Treatment of Anxiety Disorders: True Gains or False Hopes? Bulletin of Clinical Psychopharmacology 2009, 19:436-446.
• [57]Sunderland A: Do laboratory tests predict everyday memory? A neuropsychological study. J Verb Learn Verb Behav 1983, 22:341-357.
• [58]McCance-Katz EF, Sullivan LE, Nallani S: Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict 2010, 19:4-16.
• [59]Stein RA, Strickland TL: A review of the neuropsychological effects of commonly used prescription medications. Arch Clin Neuropsychol 1998, 13:259-284.
• [60]DeCoster J, Iselin AM, Gallucci M: A conceptual and empirical examination of justifications for dichotomization. Psychol Methods 2009, 14:349-366.
• [61]Kitajima R, Miyamoto S, Tenjin T, Ojima K, Ogino S, Miyake N, Fujiwara K, Funamoto Y, Arai J, Tsukahara S, et al.: Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic. Prog Neuropsychopharmacol Biol Psychiatry 2012, 36:300-306.
• [62]Kilic C, Curran HV, Noshirvani H, Marks IM, Basoglu M: Long-term effects of alprazolam on memory: a 3–5 year follow-up of agoraphobia/panic patients. Psychol Med 1999, 29:225-231.
• [63]Curran HV, Collins R, Fletcher S, Kee SCY, Woods B, Iliffe S: Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood and quality of life. Psychol Med 2003, 33:1223-1237.
• [64]Barker MJ, Greenwood KM, Jackson M, Crowe SF: Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol 2004, 19:437-454.
• [65]Hanlon JT, Rubin SM, Shorr RI, et al.: A drug burden index to define the functional burden of medications in older people. Arch Intern Med 2007, 167:781-787.
• [66]Rickels K, Lucki I, Schweizer E, Garcia-Espana F, Case WG: Psychomotor performance of long-term benzodiazepine users before, during, and after benzodiazepine discontinuation. J Clin Psychopharmacol 1999, 19:107-113.
• [67]Gruber SA, Silveri MM, Renshaw PF, Tzilos GK, Pollack M, Kaufman MJ, Yurgelun-Todd DA: Methadone maintenance improves cognitive performance after two months of treatment. Exp Clinic Psychopharmacol 2006, 14:157-164.
• [68]Bartels C, Wegrzyn M, Wiedl A, Ackermann V, Ehrenreich H: Practice effects in healthy adults: a longitudinal study on frequent repetitive cognitive testing. BMC Neurosci 2010, 11:118. BioMed Central Full Text
• [69]Basso MR, Carona FD, Lowery N, Axelrod BN: Practice effects on the WAIS-III across 3- and 6-month Intervals. Clin Neuropsychol 2002, 16:57-63.
• [70]Prosser J, Eisenberg D, Davey E, Steinfeld M, Cohen L, London E, Galynker I: Character pathology and neuropsychological test performance in remitted opiate dependence. Subst Abuse Treat Prev Policy 2008, 3:23. BioMed Central Full Text
• [71]Loeber S, Nakovics H, Kniest A, Kiefer F, Mann K, Croissant B: Factors affecting cognitive function of opiate-dependent patients. Drug Alcohol Depend 2012, 120:81-87.